|
|
| Line 1: |
Line 1: |
| '''Do Not Delete''' | | '''Do Not Delete''' |
|
| |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| |bgcolor="LightGreen" | '''a.''' LDL-C should be <100 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |bgcolor="LightGreen" |'''b.''' If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |bgcolor="LightGreen" |'''c.''' If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
| |
| |-
| |
| |bgcolor="LightGreen" |'''d.''' If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="LightGreen" |'''e.''' Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |}
| |
|
| |
| ----
| |
|
| |
| {|class="wikitable"
| |
| |-
| |
| |colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
| |
| |-
| |
| |bgcolor="LightCoral"|'''1.''' Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
| |
| |-
| |
| |bgcolor="LightCoral"|'''2.''' Ongoing clinical screening is not indicated in genotype-negative relatives in families with [[HOCM]]. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
| |
| |}
| |
| ----
| |
| {|class="wikitable"
| |
| |-
| |
| | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| |
| |-
| |
| |bgcolor="LemonChiffon"|'''a.''' Reduction of LDL-C to <70 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:A]])
| |
| |-
| |
| |bgcolor="LemonChiffon"|'''b.''' If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="LemonChiffon"|'''c.''' If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="LemonChiffon"|'''d.''' Therapeutic options to reduce non HDL - C are [[Niacin]] (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |-
| |
| |bgcolor="LemonChiffon"|'''e.''' Therapeutic options to reduce non HDL - C are [[Fibrate]] therapy (after LDL-C loweing therapy). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]])
| |
| |}
| |
|
| |
| ----
| |
|
| |
|
| Shown below is a strip from a patient being cardioverted for atrial fibrillation. The patient was taking sotalol and coumadin. This is the first shock which was set at 150 joules and delivered via defibrillator pads placed with the positive in the V1 position and the negative on the back between the left scapula and the spine. | | Shown below is a strip from a patient being cardioverted for atrial fibrillation. The patient was taking sotalol and coumadin. This is the first shock which was set at 150 joules and delivered via defibrillator pads placed with the positive in the V1 position and the negative on the back between the left scapula and the spine. |
| [[Image: Atrial Fibillation.jpg|center|800px]] | | [[Image: Atrial Fibillation.jpg|center|800px]] |
| ---- | | ---- |
